According to FutureWise analysis the market for biologics outsourcing in 2023 is US$ 95.61 billion, and is expected to reach US$ 382.43 billion by 2031 at a CAGR of 18.92%. Biologics outsourcing refers to the practice of entrusting the development, manufacturing, and testing of biologic drugs—complex molecules sourced from living organisms, including monoclonal antibodies, vaccines, and...